71% of Global Businesses Have Accelerated AI Adoption Amid Tariffs, Inflation and Uncertainty, Finds Economist Study Commissioned by Kinaxis
10.11.2025 14:00:00 EET | Business Wire | Press release
According to Supply Chain’s Big Bet on AI For Geopolitical Resilience, a new global study from Economist Impact, commissioned by Kinaxis® Inc. (TSX:KXS), while 71% of companies have accelerated AI deployment in response to tariffs, inflation, and geopolitical volatility, a wide gap remains between AI ambition and implementation, according to Economist Impact.
Nearly every company (97%) is experimenting with AI, but only 20% can make real-time decisions, and just 22% have a defined AI strategy, and those with one are more than three times as likely to see measurable ROI. Moreover, while business leaders tend to underestimate the new risks and complexities that AI may introduce, staff are more focused on the practical realities with the effort, change management, and technical challenges involved in turning AI ambition into everyday impact.
“Disruption is no longer cyclical, it’s structural, and AI has become the defining accelerator of adaptability,” said Fab Brasca, Senior Vice President, Market Strategy and Product Management at Kinaxis. “In a world of constant geopolitical and economic turbulence, companies cannot afford to experiment in isolation or chase hype. Those that orchestrate intelligence across the enterprise, by turning data into continuous decisions, will convert volatility into advantage.”
Adoption Is Up, But Action Lags
AI adoption varies widely by use case, revealing where companies are focusing their early efforts - and where critical blind spots remain.
- 52% of organizations report full integration for predictive analytics (the leading use case)
- Fewer than 15% of companies use AI for supplier monitoring, anomaly detection, or geopolitical tracking, the very risks now driving adoption.
At the same time, economic pressure is amplifying the urgency to act as companies face rising costs and supply instability.
- 79% of companies have already passed higher costs on to consumers
- More than three-quarters report worsening availability of key components
Inside organizations, a confidence gap is emerging between leadership optimism and day-to-day execution.
- Two-thirds of C-suite executives expect AI to deliver returns within 12 months
- Less than 50% of junior leaders share that view
Regional Contrasts Are Clear
- Executives in Asia-Pacific (81%) and Europe (78%) report faster AI acceleration than those in North America (57%)
- Executives in Europe (38%) and Asia-Pacific (31%) report stronger AI investment momentum than those in North America (22%), reflecting differences in regulatory environments and risk appetite
- Even in the fastest-moving regions, adoption remains shallow - just 11% use AI for scenario modeling and only 3% for geopolitical tracking.
The Blind Spot - Readiness and Governance
Fewer than one in four business leaders expect AI-related risks to increase over the next three years, revealing a major gap between confidence and capability. While companies are rapidly deploying AI to manage geopolitical and economic shocks, most are not addressing the underlying challenges of data readiness, governance, and accountability that will determine whether those investments pay off.
“The data reveal how far ambition has outpaced readiness,” said Oliver Sawbridge, senior manager, trade, and geopolitics at the Economist. “Companies are racing to deploy AI to manage geopolitical and economic shocks, but most lack the data, systems, and strategies to make it work in real time. It is a reminder that resilience depends as much on preparedness as on innovation.”
This growing disconnect highlights a key theme across the study: as AI moves from experimentation to execution, the ability to govern and scale it responsibly will define who turns adoption into advantage.
The Kinaxis View: From Automation to Adaptation in the new Agentic Age
Fewer than one in ten organizations have begun exploring agentic AI. That is where Kinaxis sees the next frontier - using AI as a foundation for adaptability, where agents and humans orchestrate together, continuously, safely, and in context. Powered by concurrency and governance guardrails, every recommendation is explainable, every action auditable, and every decision aligned to business outcomes.
The findings from Supply Chain’s Big Bet on AI For Geopolitical Resilience reinforce this vision. Real resilience is not automation for efficiency’s sake, it is intelligent adaptation. It is the difference between AI that reacts to disruption and AI that helps organizations stay ahead of it: a future built on agentic orchestration, where planning and execution move together to turn volatility into foresight and adaptability into growth.
Learn more
Download and read the full report here:www.kinaxis.com/en/economist-ai
Register for the live webinar with Kinaxis and Economist Impact on November 20 at 11 a.m. ET.
About the Study
The report is based on a survey of more than 800 senior business leaders across Europe, North America, and Asia-Pacific. Economist Impact conducted the research independently, with sponsorship from Kinaxis.
About Kinaxis
Kinaxis is a leader in modern supply chain orchestration, powering complex global supply chains, and supporting the people who manage them. Our powerful, AI-infused supply chain orchestration platform, Maestro, combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today’s volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Source: Kinaxis Inc
View source version on businesswire.com: https://www.businesswire.com/news/home/20251110649522/en/
Contacts
Media Relations
Matt Tatham | Kinaxis
mtatham@kinaxis.com
+1 917-446-7227
Investor Relations
Rick Wadsworth | Kinaxis
rwadsworth@kinaxis.com
+1 613-907-7613
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
AI Meets Traditional Culture: Huangshan Captures Widespread Attention at ITB Berlin7.3.2026 11:22:00 EET | Press release
Huangshan, one of China’s most iconic scenic destinations, drew significant attention at this year’s ITB by presenting a compelling fusion of traditional Chinese culture and cutting-edge artificial intelligence under the slogan “The world of Huangshan is for the world.” This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260307909978/en/ International visitor admires Huangshan cultural and creative exhibits at the Huangshan stand during ITB Berlin. Located in eastern China’s Anhui Province, Huangshan is famed for its “Five Natural Wonders” — fantastic pines, grotesque rocks, sea of clouds, hot spring and winter snow. The mountain is widely regarded as one of China’s greatest mountain landscapes. It is also a rare natural heritage site that simultaneously holds multiple international designations, including UNESCO World Cultural and Natural Heritage status, a UNESCO Global Geopark and a World Biosphere Reserve. At ITB, the Huangsh
Incyte Announces the European Commission Approval of Zynyz ® (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)6.3.2026 23:42:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that the European Commission (EC) has approved Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “The EC approval of Zynyz marks an important step forward for patients with advanced SCAC, a rare cancer for which meaningful treatment advances have not occurred in several decades,” said Bill Meury, President and Chief Executive Officer, Incyte. “As the first PD-1 immunotherapy approved in Europe in combination with platinum-based chemotherapy in the first-line setting, Zynyz helps expand the standard-of-care options available to clinicians and underscores our commitment to delivering innovative medicines that can have an impact for patients.” The EC decision follows the January 2026 positive opinion received from the European Medicines Agency’s Committee f
Dfns Launches Payouts6.3.2026 22:27:00 EET | Press release
Dfns today announced the launch of Payouts, a new API enabling institutions to convert stablecoins to fiat and route payouts across multiple bank accounts while keeping wallet-level governance and controls in place. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260305327930/en/ Convert stablecoins to fiat and settle payouts to bank accounts in 94 countries, today. Solving the problem of single-rail off-ramps Today, most fintechs and institutions still hard-wire a single payout provider into their stack, or rely on vertically integrated models that bundle routing, pricing, custody, and settlement together. That approach may be convenient early on, but it creates structural problems at scale: weak price discovery because there is no competitive pressure on margins, limited auditability because routing decisions are opaque, and operational fragility because a single provider degradation in any corridor requires architectural i
Klarna Group Plc Clarifies Mechanics of March 9 Lock-Up Expiration6.3.2026 21:23:00 EET | Press release
Klarna Group plc (NYSE: KLAR) today issues the following clarification to ensure investors and market participants have accurate information regarding the mechanics of its lock-up expiration on March 9, 2026, the processes required before pre-IPO shares can be traded on the NYSE, and the prior liquidity opportunities already available to shareholders. This release contains only factual descriptions of the Company's share structure and applicable processes. It does not constitute guidance or a projection of any kind regarding future trading volumes, share price, or the intentions of any shareholder and speaks only as of the date of this press release. 1. 335 million locked-up shares — but two different categories Of the 378 million total ordinary shares outstanding, approximately 335 million are subject to lock-up restrictions expiring March 9, 2026. However, these shares fall into two distinct categories governed by separate sets of regulations. A. 159 million shares (48% of locked-up
Lone Star Funds Announces Agreement to Acquire the Capsules & Health Ingredients Division of Lonza Group AG6.3.2026 19:30:00 EET | Press release
Lone Star Funds (“Lone Star”) today announced that an affiliate of Lone Star Fund XII, L.P. has entered into a definitive agreement to acquire the Capsules & Health Ingredients (“CHI”) division of Lonza Group AG. As part of the transaction, Lonza will retain a 40% equity position in the business. Headquartered in Basel, Switzerland, CHI operates globally across the Americas, Europe and Asia Pacific. The business comprises three segments: Hard Empty Capsules: leading global manufacturer of gelatin and plant-based capsules offering a broad range of innovative solutions for pharmaceutical and nutraceutical customers. Dosage Form Solutions: end-to-end development and manufacturing platform serving nutraceutical and pharmaceutical customers. Health Ingredients: provider of branded, science-backed nutrition ingredients serving joint health, energy and active lifestyle markets. Lone Star believes CHI is a high-quality, globally recognized platform with strong technical capabilities, different
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom